3.980EUR-0.99%Mkt Cap: —P/E: —1d ago
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in F…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value1.03B $
Revenue (TTM)7.35M $
Gross Profit7.33M $
Net Income (TTM)-384.93M $
Revenue/Share0.0391 USD
Last Price3.980 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees69
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINFR0013233012
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.15
EV/Revenue140.12
P/S—
P/B-26.05
EPS (TTM)-1.27
EPS (Forward)—
52W Range
3.85545% of range4.135
52W High4.135 EUR
52W Low3.855 EUR
Profitability
Gross Margin99.68%
Oper. Margin-6710.69%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-45.08%
Growth
Revenue Growth-89.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-114.00M $
CapEx (TTM)—
FCF Margin-2968.67%
FCF Yield—
Net Debt142.45M $
Net Debt/EBITDA-0.99
Balance Sheet
Debt/Equity—
Current Ratio3.16
Quick Ratio1.41
Book Value/Sh-0.1480 EUR
Cash/Share0.4810 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.22.26M
Float157.92M
Insiders12.67%
Institutions49.71%
Technical
SMA 503.573 (+11.4%)
SMA 2003.586 (+11.0%)
Beta0.91
S&P 52W Chg20.80%
Avg Vol (30d)4.24K
Avg Vol (10d)1.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—